Skip to main content

Table 3 Noncompartmental pharmacokinetics in cerebrospinal fluid by dose following single dosing with GSK933776 a

From: Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study

Parameters

Median (range)

 

1 mg/kg ( N/n = 6/3)

3 mg/kg ( N/n = 6/6)

6 mg/kg ( N/n = 6/4)

AUC0–4 (h∙mg/ml)

0.0 (0.0 to 71.1)

0.0 (0.0 to 32.1)

0.0 (0.0 to 38.9)

AUC5–12 (h∙mg/ml)

87.9 (12.7 to 134.9)

54.8 (6.3 to 398.8)

140.2 (49.1 to 626.5)

AUC0–12 (h∙mg/ml)

87.9 (12.7 to 210.9)

54.8 (6.3 to 456.0)

140.2 (49.1 to 703.9)

AUC0–t (h∙mg/ml)

6.3 (0.0 to 339.5)

54.8 (6.3 to 456.0)

88.1 (0.0 to 703.9)

C max (μg/ml)

12.7 (0.0 to 47.8)

20.1 (12.5 to 84.1)

28.5 (0.0 to 116.9)

C t (μg/ml)

19.0 (11.4 to 25.3)

19.6 (12.5 to 84.1)

47.9 (18.6 to 116.1)

t max (h)

10.0 (2.0 to 11.0)

11.8 (10.0 to 12.0)

12.0 (11.0 to 12.0)

t last (h)

17.0 (11.0 to 19.0)

12.0 (11.6 to 12.0)

12.0 (12 to 12)

t lag (h)

8.0 (0.0 to 10.0)

8.5 (2.0 to 11.0)

5.0 (2.0 to 8.0)

  1. aAUC0–4: Area under the cerebrospinal fluid (CSF) concentration–time curve from time 0 to 4 hours postdosing; AUC0–12: Area under the CSF concentration–time curve from time 0 to 12 hours postdosing; AUC5–12: Area under the CSF concentration–time curve from 5 to 12 hours postdosing; AUC0–t : Area under the CSF concentration–time curve to the last quantifiable concentration; C max: Maximum CSF concentration; C t: Concentration at t last; N: Number of patients who received GSK933776; n: Number of patients from whom quantifiable CSF pharmacokinetics concentration levels were obtained and analysed; t last: Time of the last observed CSF concentration; t max: Time of occurrence of C max; t lag: Time prior to the first measurable (that is, nonzero) concentration in CSF.
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193